Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. Apontis Pharma AG
  6. News
  7. Summary
    APPH   DE000A3CMGM5

APONTIS PHARMA AG

(APPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Apontis Pharma AG Announces Unaudited Preliminary Earnings Results for the First Half of 2021

07/28/2021 | 01:30am EDT

Apontis Pharma AG announced unaudited preliminary earnings results for the first half of 2021. For the half year, the company reported total revenues of EUR 24.0 million against EUR 17.735 million a year ago.


© S&P Capital IQ 2021
All news about APONTIS PHARMA AG
09/14APONTIS PHARMA : To Launch New Single Pill For Hypertension, Hyperlipidemia
MT
09/14APONTIS PHARMA : announces launch of new Single Pill for more efficient treatmen..
EQ
09/14PRESS RELEASE : APONTIS PHARMA announces launch of new Single Pill for more effi..
DJ
09/14Apontis Pharma AG Announces Launch of New Single Pill for More Efficient Trea..
CI
08/11APONTIS PHARMA : builds on strong position and profitability in first half of 20..
EQ
08/11PRESS RELEASE : APONTIS PHARMA builds on strong position and profitability in fi..
DJ
07/28APONTIS PHARMA : reports accelerated growth in first half of 2021 - Single Pill ..
EQ
07/28PRESS RELEASE : APONTIS PHARMA reports accelerated growth in first half of 2021 ..
DJ
07/28Apontis Pharma AG Provides Earnings Guidance for the Financial Year 2021
CI
07/28Apontis Pharma AG Announces Unaudited Preliminary Earnings Results for the Fi..
CI
More news
Financials
Sales 2021 49,3 M 57,8 M 57,8 M
Net income 2021 1,55 M 1,82 M 1,82 M
Net cash 2021 27,5 M 32,2 M 32,2 M
P/E ratio 2021 132x
Yield 2021 -
Capitalization 208 M 244 M 244 M
EV / Sales 2021 3,67x
EV / Sales 2022 3,08x
Nbr of Employees 195
Free-Float 100%
Chart APONTIS PHARMA AG
Duration : Period :
Apontis Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 24,50 €
Average target price 36,50 €
Spread / Average Target 49,0%
EPS Revisions
Managers and Directors
Karlheinz Gast Chief Executive Officer
Edin Hadzic Chairman-Supervisory Board
Olaf Randerath Head-Medical Affairs
Olaf Elbracht Member-Supervisory Board
Christopher Friedel Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
APONTIS PHARMA AG0.00%245
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.84%209 456